169 related articles for article (PubMed ID: 38129282)
1. Prognostic impact of radiological tumor burden in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Katayama S; Iwata T; Kawada T; Okamoto Y; Sano Y; Kawago Y; Miyake S; Moriwake T; Kuinose A; Horikawa Y; Tsuboi K; Tsuboi I; Sakaeda K; Nakatsuka H; Takamoto A; Hirata T; Shirasaki Y; Yamasaki T; Morinaka H; Nagasaki N; Hara T; Ochi A; Okumura M; Watanabe T; Sekito T; Kawano K; Horii S; Yamanoi T; Nagao K; Yoshinaga K; Maruyama Y; Tominaga Y; Sadahira T; Nishimura S; Edamura K; Kobayashi T; Kusumi N; Kurose K; Yamamoto Y; Sugimoto M; Nakada T; Sasaki K; Takenaka T; Ebara S; Miyaji Y; Wada K; Kobayashi Y; Araki M
Urol Oncol; 2024 Mar; 42(3):70.e11-70.e18. PubMed ID: 38129282
[TBL] [Abstract][Full Text] [Related]
2. Effect of Antacids on the Survival of Patients With Metastatic Urothelial Carcinoma Treated With Pembrolizumab.
Sekito T; Bekku K; Katayama S; Watanabe T; Tsuboi I; Yoshinaga K; Maruyama Y; Yamanoi T; Kawada T; Tominaga Y; Sadahira T; Iwata T; Nishimura S; Kusumi N; Edamura K; Kobayashi T; Kurose K; Ichikawa T; Miyaji Y; Wada K; Kobayashi Y; Araki M
Clin Genitourin Cancer; 2024 Aug; 22(4):102097. PubMed ID: 38763123
[TBL] [Abstract][Full Text] [Related]
3. Sex hormones influence survival of patients with metastatic urothelial carcinoma undergoing immune checkpoint therapy.
Lindner AK; Lackner F; Tymoszuk P; Barth DA; Seeber A; Kocher F; Toth B; Hochleitner M; Pichler M; Pichler R
Biol Sex Differ; 2023 Jun; 14(1):38. PubMed ID: 37277835
[TBL] [Abstract][Full Text] [Related]
4. Association between lung immune prognostic index and survival of patients with metastatic urothelial carcinoma treated with pembrolizumab.
Nakamura K; Ishiyama Y; Nemoto Y; Ishihara H; Tachibana H; Fukuda H; Shinmura H; Hashimoto Y; Yoshida K; Iizuka J; Ishida H; Kondo T; Takagi T
Int J Clin Oncol; 2023 Jul; 28(7):913-921. PubMed ID: 37103730
[TBL] [Abstract][Full Text] [Related]
5. Antibiotic use and survival of patients receiving pembrolizumab for chemotherapy-resistant metastatic urothelial carcinoma.
Ishiyama Y; Kondo T; Nemoto Y; Kobari Y; Ishihara H; Tachibana H; Yoshida K; Hashimoto Y; Takagi T; Iizuka J; Tanabe K
Urol Oncol; 2021 Dec; 39(12):834.e21-834.e28. PubMed ID: 34284929
[TBL] [Abstract][Full Text] [Related]
6. Modified Glasgow Prognostic Score 2 as a Prognostic Marker in Patients With Metastatic Urothelial Carcinoma.
Nagai T; Naiki T; Isobe T; Sugiyama Y; Etani T; Iida K; Nozaki S; Noda Y; Shimizu N; Tasaki Y; Mimura Y; Banno R; Kubota H; Hamamoto S; Kawai N; Yasui T
In Vivo; 2021; 35(5):2793-2800. PubMed ID: 34410970
[TBL] [Abstract][Full Text] [Related]
7. Effects of Proton Pump Inhibitors on Survival Outcomes in Patients with Metastatic or Unresectable Urothelial Carcinoma Treated with Pembrolizumab.
Kunimitsu Y; Morio K; Hirata S; Yamamoto K; Omura T; Hara T; Harada K; Fujisawa M; Yano I
Biol Pharm Bull; 2022; 45(5):590-595. PubMed ID: 35491164
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness and safety profile of pembrolizumab for metastatic urothelial cancer: A retrospective single-center analysis in Japan.
Fujiwara M; Yuasa T; Urasaki T; Komai Y; Fujiwara R; Numao N; Yamamoto S; Yonese J
Cancer Rep (Hoboken); 2021 Dec; 4(6):e1398. PubMed ID: 33934570
[TBL] [Abstract][Full Text] [Related]
9. FAN score comprising fibrosis-4 index, albumin-bilirubin score and neutrophil-lymphocyte ratio is a prognostic marker of urothelial carcinoma patients treated with pembrolizumab.
Kawashima A; Yamamoto Y; Sato M; Nakata W; Kakuta Y; Ishizuya Y; Yamaguchi Y; Yamamoto A; Yoshida T; Takayama H; Takada T; Inoue H; Okuda Y; Kato T; Hatano K; Uemura M; Nonomura N; Imamura R
Sci Rep; 2021 Oct; 11(1):21199. PubMed ID: 34707147
[TBL] [Abstract][Full Text] [Related]
10. Pretreatment clinical and hematologic prognostic factors of metastatic urothelial carcinoma treated with pembrolizumab: a systematic review and meta-analysis.
Yanagisawa T; Mori K; Katayama S; Mostafaei H; Quhal F; Laukhtina E; Rajwa P; Motlagh RS; Aydh A; König F; Grossmann NC; Pradere B; Miki J; Kimura T; Egawa S; Shariat SF
Int J Clin Oncol; 2022 Jan; 27(1):59-71. PubMed ID: 34757531
[TBL] [Abstract][Full Text] [Related]
11. Rethinking prognostic factors in locally advanced or metastatic urothelial carcinoma in the immune checkpoint blockade era: a multicenter retrospective study.
Ruiz-Bañobre J; Molina-Díaz A; Fernández-Calvo O; Fernández-Núñez N; Medina-Colmenero A; Santomé L; Lázaro-Quintela M; Mateos-González M; García-Cid N; López-López R; Vázquez S; Anido-Herranz U
ESMO Open; 2021 Apr; 6(2):100090. PubMed ID: 33740735
[TBL] [Abstract][Full Text] [Related]
12. Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
Etani T; Naiki T; Sugiyama Y; Nagai T; Iida K; Noda Y; Shimizu N; Tasaki Y; Mimura Y; Okada T; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
Oncology; 2020; 98(12):876-883. PubMed ID: 32862183
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of enfortumab vedotin between patients with metastatic urothelial carcinoma who were treated with avelumab or pembrolizumab: real-world data from a multi-institutional study in Japan.
Hirasawa Y; Adachi T; Hashimoto T; Fukuokaya W; Koike Y; Yata Y; Komura K; Uchimoto T; Tsujino T; Nishimura K; Takahara K; Saruta M; Fujita K; Hashimoto M; Uemura H; Shiroki R; Azuma T; Kimura T; Ohno Y
J Cancer Res Clin Oncol; 2024 Apr; 150(4):182. PubMed ID: 38592548
[TBL] [Abstract][Full Text] [Related]
14. Association between comorbidities and survival in patients with metastatic urothelial carcinoma treated with pembrolizumab.
Hashimoto M; Fukuokaya W; Yanagisawa T; Yamamoto S; Koike Y; Imai Y; Iwatani K; Onuma H; Ito K; Urabe F; Tsuzuki S; Kimura S; Oyama Y; Abe H; Miki J; Kimura T
Int J Clin Oncol; 2024 May; 29(5):612-619. PubMed ID: 38430304
[TBL] [Abstract][Full Text] [Related]
15. Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO; Matsubara N; Park SH; Huddart RA; Burgess EF; Özgüroğlu M; Valderrama BP; Laguerre B; Basso U; Triantos S; Akapame S; Kean Y; Deprince K; Mukhopadhyay S; Loriot Y;
Ann Oncol; 2024 Jan; 35(1):107-117. PubMed ID: 37871702
[TBL] [Abstract][Full Text] [Related]
16. Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era.
Holmsten K; Eknert J; Öfverholm E; Papantoniou D; Jawdat F; Verbiéné I; Laurell A; Jänes E; Sandzén J; Wojtyna-Dziedzic E; Lagstam I; Söderkvist K; Costa Svedman F; Liedberg F; Bruzelius M; Fransson AS; Kjellström S; Omland LH; Pappot H; Ullén A
Clin Genitourin Cancer; 2023 Dec; 21(6):e438-e448. PubMed ID: 37308329
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the Immunotherapy Response Evaluation Criteria in Solid Tumours (iRECIST) with RECIST for capturing treatment response of patients with metastatic urothelial carcinoma treated with pembrolizumab.
Fukuokaya W; Kimura T; Yanagisawa T; Kimura S; Tsuzuki S; Koike Y; Iwamoto Y; Enei Y; Tanaka M; Urabe F; Onuma H; Honda M; Miki J; Oyama Y; Abe H; Egawa S
BJU Int; 2021 Jan; 127(1):90-95. PubMed ID: 32662189
[TBL] [Abstract][Full Text] [Related]
18. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study.
Massari F; Santoni M; Takeshita H; Okada Y; Tapia JC; Basso U; Maruzzo M; Scagliarini S; Büttner T; Fornarini G; Myint ZW; Galli L; Souza VC; Pichler R; De Giorgi U; Gandur N; Lam ET; Gilbert D; Popovic L; Grande E; Mammone G; Berardi R; Crabb SJ; Kemp R; Molina-Cerrillo J; Freitas M; Luz M; Iacovelli R; Calabrò F; Tural D; Atzori F; Küronya Z; Chiari R; Campos S; Caffo O; Fay AP; Kucharz J; Zucali PA; Rinck JA; Zeppellini A; Bastos DA; Aurilio G; Mota A; Trindade K; Ortega C; Sade JP; Rizzo M; Fiala O; Vau N; Giannatempo P; Barillas A; Monteiro FSM; Dauster B; Mennitto A; Nogueira L; de Carvalho Fernandes R; Seront E; Aceituno LG; Grillone F; Cutuli HJ; Fernandez M; Bassanelli M; Kopp RM; Roviello G; Abahssain H; Procopio G; Milella M; Kopecky J; Martignetti A; Messina C; Caitano M; Inman E; Kanesvaran R; Herchhorn D; Santini D; Bamias A; Bisonni R; Mosca A; Morelli F; Maluf F; Soares A; Nunes F; Pinto A; Zgura A; Incorvaia L; Ansari J; Zabalza IO; Landmesser J; Rizzo A; Mollica V; Marchetti A; Rosellini M; Sorgentoni G; Battelli N; Buti S; Porta C; Bellmunt J
Cancer Immunol Immunother; 2024 Apr; 73(6):106. PubMed ID: 38634928
[TBL] [Abstract][Full Text] [Related]
19. Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Isobe T; Naiki T; Sugiyama Y; Naiki-Ito A; Nagai T; Etani T; Nozaki S; Iida K; Noda Y; Shimizu N; Tomiyama N; Banno R; Kubota H; Hamamoto S; Ando R; Kawai N; Yasui T
Int J Clin Oncol; 2022 Jan; 27(1):165-174. PubMed ID: 34633579
[TBL] [Abstract][Full Text] [Related]
20. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors.
Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS
Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
